Drugs / D-SUIV cH5/1N1+AS01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03275389 | Sep 2017 → Mar 2020 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D-SUIV cH5/1N1+AS01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03275389 ↗ |
| Route | Intramuscular | “1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 01 (AS01) was administered IM in the...” NCT03275389 ↗ |